{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025814","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.215069+00:00","generated_at":"2026-05-17T15:07:58.332720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase","bullets":["Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.","Phase 2b RewinD-LB extension: neflamapimod reduced risk of clinically significant worsening by 54% (p=0.0037) on CDR-SB at 32 weeks.","In patients with minimal AD co-pathology (ptau181<2.2), risk reduction improved to 64% (p=0.0001).","Significant decrease in plasma GFAP biomarker: -18.4 pg/mL from baseline in active group vs +1.1 pg/mL increase in placebo at Week 16.","Plans to meet FDA in Q4 2025 to align on Phase 3 trial design; Phase 3 initiation mid-2026 subject to funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025814","json":"https://secwatch.observer/filing/0001437749-25-025814.json","markdown":"https://secwatch.observer/filing/0001437749-25-025814.md","text":"https://secwatch.observer/filing/0001437749-25-025814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/0001437749-25-025814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/crvo20250808_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:07:58.332720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}